

Precision medicine is the future of allergy care

At the start of 2022, Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), announced that it has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine. Through this collaboration, Stallergenes Greer underscores once more its commitment to advancing precision medicine for allergy sufferers.

Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). Precision medicine consists of using the individual characteristics and mechanism of disease of each patient to determine which treatment is the most likely to maximise treatment effectiveness, while reducing costs both for patients and healthcare authorities.

“At Stallergenes Greer, we believe that patients deserve an allergen immunotherapy solution that is tailored to their needs and profile,” a company spokesperson explains. “We are pushing the boundaries of R&D to fully leverage the potential of precision medicine for the benefit of people with allergies. One of the

ways we are doing this is by characterising the molecular immunological responses of each patient and exploring molecular diagnostics to identify, with increased precision, the allergens to which each patient is specifically sensitive.”

The long-term research collaboration, which combines the long-standing expertise of Stallergenes Greer in AIT with the prestigious research capabilities of Imperial College London, aims to identify biomarkers of AIT efficacy and expanding the knowledge of the pathophysiology of allergic diseases and their treatment with AIT. “This collaboration will bring new insights and foster our endotype-driven approach to allow allergologists, pediatricians, ENTs and pneumologists tailor treatment modalities with the right dosing at the right time for allergic patients.”

According to the World Health Organization, in a world affected by climate-change, environmental pollution and urbanisation, more and more people are affected by allergies and, globally,

among school children, sensitisation rates to one or more common allergens, including food, are currently approaching 40%-50%.

Stallergenes Greer’s spokesperson also notes that the development of new disciplines and skills are making it possible to specify the diagnosis of respiratory allergy for each individual. Molecular diagnostics provide additional information to guide the prescription and composition of allergen immunotherapy treatments.

“Because each patient presents a unique immunologic profile, we believe that one solution doesn’t fit all. We are now in a position to broaden our outlook to the 2025 horizon, in particular with regard to the development of a robust pipeline based on novel technologies and precision medicine, the expansion of our geographic footprint and a presence in the field of food allergies.”

STALLERGENES  GREER

Head office
Zugerstrasse 76B, 6340 Baar
Switzerland
www.stallergenesgreer.com

